Abstract mRNA vaccines have emerged as a revolutionary tool to generate rapid and
precise immune responses against infectious diseases and cancers. Compared with …

Members of the coronaviridae family are endemic to human populations and have caused
several epidemics and pandemics in recent history. In this review, we will discuss the …

Checkpoint inhibitor (CPI) therapies provide limited benefit to patients with tumors of low
immune reactivity. T cell-inducing vaccines hold promise to exert long-lasting disease …

Abstract mRNA vaccines were the first to be authorized for use against SARS-CoV-2 and
have since demonstrated high efficacy against serious illness and death. However …

The approved worldwide use of two messenger RNA (mRNA) vaccines (BNT162b2 and
mRNA-1273) in late 2020 has proven the remarkable success of mRNA therapeutics …

SARS-CoV-2 has resulted in high levels of morbidity and mortality world-wide, and severe
complications can occur in older populations. Humoral immunity induced by authorized …

Several vaccines have been widely used to counteract the global pandemic caused by
SARS-CoV-2. However, due to the rapid emergence of SARS-CoV-2 variants of concern …

The mRNA technology has emerged as a rapid modality to develop vaccines during
pandemic situations with the potential to protect against endemic diseases. The success of …

The optimal vaccination strategy to boost responses in the context of pre-existing immune
memory to the SARS-CoV-2 spike (S) glycoprotein is an important question for global public …

In the light of the lack of authorized COVID-19 vaccines adapted to the Omicron variant
lineage, the administration of the first and second booster dose is recommended. It remains …